ASPS-1, A Novel Cell Line Manifesting Key Features of Alveolar Soft Part Sarcoma
暂无分享,去创建一个
R. Shoemaker | D. Schrump | M. Hollingshead | S. Kenney | S. Burkett | L. Stockwin | S. Borgel | D. Vistica | Donna O. Butcher
[1] R. Shoemaker,et al. Abstract 3415: Therapeutic targeting of the ASPL-TFE3 gene fusion in ASPS-1, a novel cell line derived from metastatic alveolar soft part sarcoma (ASPS) , 2010 .
[2] Wei-Lien Wang,et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray , 2009, Histopathology.
[3] R. Shoemaker,et al. Therapeutic Vulnerability of an In Vivo Model of Alveolar Soft Part Sarcoma (ASPS) to Antiangiogenic Therapy , 2009, Journal of pediatric hematology/oncology.
[4] R. Shoemaker,et al. BMC Cancer BioMed Central Research article Gene expression profiling of alveolar soft-part sarcoma (ASPS) , 2009 .
[5] E. Rankin,et al. The role of hypoxia-inducible factors in tumorigenesis , 2008, Cell Death and Differentiation.
[6] W. Stetler-Stevenson. The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2 , 2008, Cancer and Metastasis Reviews.
[7] R. Shoemaker,et al. Immunohistochemical Discrimination Between the ASPL-TFE3 Fusion Proteins of Alveolar Soft Part Sarcoma , 2008, Journal of pediatric hematology/oncology.
[8] A. Lazar,et al. Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part Sarcoma , 2007, Clinical Cancer Research.
[9] S. Rocha. Gene regulation under low oxygen: holding your breath for transcription. , 2007, Trends in biochemical sciences.
[10] M. Ladanyi,et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. , 2007, Cancer research.
[11] A. Folpe,et al. Alveolar soft-part sarcoma: a review and update , 2006, Journal of Clinical Pathology.
[12] N. Scamuffa,et al. Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases , 2006, Medicinal research reviews.
[13] A. Basak. Inhibitors of proprotein convertases , 2005, Journal of Molecular Medicine.
[14] Napoleone Ferrara,et al. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. , 2005, Biochemical and biophysical research communications.
[15] R. Shoemaker,et al. Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts , 2004, Cancer Research.
[16] P. Reynolds,et al. Midkine Is Regulated by Hypoxia and Causes Pulmonary Vascular Remodeling* , 2004, Journal of Biological Chemistry.
[17] Y. Pommier,et al. Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.
[18] D. Burkin,et al. The muscle integrin binding protein (MIBP) interacts with α7β1 integrin and regulates cell adhesion and laminin matrix deposition , 2003 .
[19] P. Wingfield,et al. TIMP-2 Mediated Inhibition of Angiogenesis An MMP-Independent Mechanism , 2003, Cell.
[20] D. Scudiero,et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.
[21] N. Seidah,et al. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. , 2002, The American journal of pathology.
[22] Alfons Meindl,et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 , 2001, Oncogene.
[23] R. Mayne,et al. A Novel Muscle-Specific β1 Integrin Binding Protein (Mibp) That Modulates Myogenic Differentiation , 1999, The Journal of cell biology.
[24] E. Vámos,et al. Alveolar soft‐part sarcoma: Further evidence by FISH for the involvement of chromosome band 17q25 , 1998, Genes, chromosomes & cancer.
[25] D. Steiner,et al. Proteolytic Processing Mechanisms in the Biosynthesis of Neuroendocrine Peptides: The Subtilisin-like Proprotein Convertases , 1995, Frontiers in Neuroendocrinology.
[26] D. Scudiero,et al. New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.
[27] F. W. Foote,et al. Alveolar soft‐part sarcomas. Structurally characteristic tumors of uncertain histogenesis , 1952, Cancer.
[28] F. Calvo,et al. The potential anti-tumorigenic and anti-metastatic side of the proprotein convertases inhibitors. , 2009, Recent patents on anti-cancer drug discovery.
[29] D. Burkin,et al. The muscle integrin binding protein (MIBP) interacts with alpha7beta1 integrin and regulates cell adhesion and laminin matrix deposition. , 2003, Developmental biology.
[30] H. Cohen,et al. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] M. Cumming,et al. Antiangiogenic potential of camptothecin and topotecan , 1999, Cancer Chemotherapy and Pharmacology.
[32] N. Seidah,et al. Pro-protein convertases of subtilisin/kexin family. , 1994, Methods in enzymology.